Compare McKesson Corporation (MCK) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs NIO Inc. — how do they compare? McKesson Corporation trades at $932.14 (market cap $108.46B), while NIO Inc. trades at $3.54 (market cap $8.62B). The key difference: McKesson Corporation is far larger — about 12.6× NIO Inc.'s market cap, and McKesson Corporation pays a 0.4% dividend while NIO Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and NIO Inc. for 81 Days on average.
| MCK | NIO | |
|---|---|---|
Market Cap | $108.46B | $8.62B |
Volume | 712,607 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $7.46 |
52-Week Low | $725.17 | $3.37 |
Typical Hold Time | 74 Days | 81 Days |
Enterprise Value | $115.00B | $6.52B |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
NIO trades at $3.54, up 1.72% today but near a 52-week low, with a bearish technical signal. Revenue grew to $87.49B in 2025, yet net losses persist at -$15.57B, though margins improved. Recent Q3 2026 deliveries rose 25.4%, and a strategic battery-swap partnership with Geely aims to expand network utilization, valued at $2.38B.
The outlook hinges on scaling profitability amid a brutal EV price war. Analysts see 76% upside to a $6.23 target, but high debt and cash burn pose risks. Sentiment is mixed, with news highlighting growth potential against competitive and macroeconomic headwinds in China.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
